Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Trial of Temsirolimus (CCI-779, Pfizer, Inc.) in Combination With Etoposide and Cyclophosphamide in Children With Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkins Lymphoma

NCT01614197 is registered in ClinicalTrials.gov with Therapeutic Advances in Childhood Leukemia Consortium as lead sponsor.

NCT NCT01614197
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01614197 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Trial of Temsirolimus (CCI-779, Pfizer, Inc.) in Combination With Etoposide and Cyclophosphamide in Children With Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkins Lymphoma
Lead sponsor
Therapeutic Advances in Childhood Leukemia Consortium
Phase
Phase 1
Overall status
Completed
Start date
July 3, 2015
Completion date
September 4, 2020
Enrollment
16 (actual)
Sites
32

Conditions

As the registry lists them; a condition with its own page is linked.

lymphoblastic leukemia, acute, childhood, lymphoblastic lymphoma, peripheral t-cell lymphoma